3,5-二羟基苄胺 | 90817-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3,5-二羟基苄胺
• 英文名称: 3,5-dihydroxybenzylamine
• 英文别名: 3,5-Dihydroxy-benzylamin；5-(Aminomethyl)benzene-1,3-diol
• CAS: 90817-33-7
• 化学式: C₇H₉NO₂
• mdl: MFCD03410986
• 分子量: 139.154
• InChiKey: AZQGXRRASGSLAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-二羟基苄胺 、 2,6-二氯-9-异丙基-9h-嘌呤 在 三乙胺 作用下， 以 正丁醇 为溶剂， 生成
  参考文献：
  名称：

  The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe Mössbauer), theoretical, and biological activity studies

  摘要：

  The first Fe-III complexes 1-6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(L-n)Cl-3]center dot nH(2)O (n = 0 for 1, 1 for 2, 2 for 3-6; L-1-L-6 = C2- and phenyl-substituted CDK inhibitors derived from 6-benzyl-amino-9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, Fe-57 Mossbauer, H-1 and C-13 NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S = 5/2) Fe-III complexes with an admixture of an S = 3/2 spin state originating probably from five-coordinated Fe-III ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82 mu(eff)/mu(B)) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the Fe-III ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4-23 mu M) and inhibition activity (IC50: 0.02-0.09 mu M) results have been achieved in the case of complexes 2-4, and complexes 3,4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L-1, L-4 and L-5, is also described. (C) 2009 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.jinorgbio.2009.12.002
• 作为产物：
  描述：

  3,5-二甲氧基苄胺 在 氢溴酸 作用下， 生成 3,5-二羟基苄胺
  参考文献：
  名称：

  Photochemical synthesis of 1,2,3,4-tetrahydroisoquinolin-3-ones from N-chloroacetylbenzylamines

  摘要：

  DOI：

  10.1016/s0040-4020(77)80005-7

文献信息

• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• Nitric oxide donating derivatives for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080024A1

  公开（公告）日：2005-04-14

  Compounds comprising nitric oxide derivatives of stilbenes, polyphenols and flavonoids and methods of their use are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  本发明提供了由stilbenes、多酚和类黄酮的亚硝酸盐衍生物组成的化合物，以及它们的使用方法，用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者。
• Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080021A1

  公开（公告）日：2005-04-14

  Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  提供了用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者的化合物和方法。
• SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS
  申请人：Zatloukal Marek

  公开号：US20130040908A1

  公开（公告）日：2013-02-14

  Substitution derivatives of N 6 -benzyladenosine-5′-monophosphate of the general formula I, wherein (R) n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C 1 to C 8 alkyl, C 1 to C 8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. A Method for their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives is also disclosed.

  通式I的N6-苄基腺苷-5'-磷酸的取代衍生物，其中（R）n表示1至4个取代基（n在1-4范围内），可以相同也可以不同，R选自包括C1到C8烷基，C1到C8烷氧基，氨基，卤素，羟基，巯基和硝基基团的群体，并且其药用盐。还公开了它们的制备方法，作为药物和其他应用中的使用，以及含有这些衍生物的治疗组合物。